Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Ocular Therapeutix, Inc. reported revenue of $52M, down 18.5% year over year. Operating margin was -519.8% and net margin -511.9%, on a free-cash-flow margin of -417.5% with capital expenditure at 23.1% of revenue. Every figure is computed directly from OCUL's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $52M | -519.8% | -511.9% |
| FY2024 | $64M | -269.6% | -303.7% |
| FY2023 | $58M | -141.0% | -138.1% |
| FY2022 | $51M | -152.7% | -138.0% |
| FY2021 | $44M | -179.3% | -15.1% |
How does OCUL compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.